BRPI0513706A - anticorpo policlonal recombinante anti-rhesus d e métodos de produção - Google Patents

anticorpo policlonal recombinante anti-rhesus d e métodos de produção

Info

Publication number
BRPI0513706A
BRPI0513706A BRPI0513706-3A BRPI0513706A BRPI0513706A BR PI0513706 A BRPI0513706 A BR PI0513706A BR PI0513706 A BRPI0513706 A BR PI0513706A BR PI0513706 A BRPI0513706 A BR PI0513706A
Authority
BR
Brazil
Prior art keywords
rhd
polyclonal antibody
collection
recombinant polyclonal
recombinant
Prior art date
Application number
BRPI0513706-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Soren Kofoed Rasmussen
Anne Bondgaard Tolstrup
Soren Bregenholt Frederiksen
John Haurum
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of BRPI0513706A publication Critical patent/BRPI0513706A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0513706-3A 2004-07-20 2005-07-18 anticorpo policlonal recombinante anti-rhesus d e métodos de produção BRPI0513706A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401133 2004-07-20
DKPA200401992 2004-12-22
PCT/DK2005/000501 WO2006007850A1 (en) 2004-07-20 2005-07-18 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture

Publications (1)

Publication Number Publication Date
BRPI0513706A true BRPI0513706A (pt) 2008-05-13

Family

ID=35159789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513706-3A BRPI0513706A (pt) 2004-07-20 2005-07-18 anticorpo policlonal recombinante anti-rhesus d e métodos de produção

Country Status (13)

Country Link
US (2) US8198415B2 (https=)
EP (2) EP1771483A1 (https=)
JP (1) JP4926054B2 (https=)
KR (1) KR20070038556A (https=)
AU (1) AU2005263331B8 (https=)
BR (1) BRPI0513706A (https=)
CA (1) CA2574062A1 (https=)
EA (1) EA014182B1 (https=)
IL (1) IL179658A (https=)
MX (1) MX2007000644A (https=)
NO (1) NO20070927L (https=)
NZ (1) NZ552265A (https=)
WO (1) WO2006007850A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ES2273202T3 (es) * 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
PT2121920E (pt) 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
WO2008106980A2 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
HRP20100640T1 (hr) 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
CA2695309A1 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
US20090093004A1 (en) * 2007-10-04 2009-04-09 Symphogen A/S Potency assay
CA2702322A1 (en) * 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110047258A (ko) * 2008-08-26 2011-05-06 심포젠 에이/에스 저혈소판증의 치료 방법
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
RU2011111725A (ru) * 2008-08-29 2012-10-10 Симфоген А/С (Dk) Способ клонирования антител птиц
US20110224094A1 (en) * 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
LT2864346T (lt) * 2012-06-21 2019-01-25 Synthon Biopharmaceuticals B.V. Antikūnų gryninimo metodas
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017184973A1 (en) 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
CN112513074A (zh) * 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
CN113661173B (zh) 2019-03-29 2024-10-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法
US12479908B2 (en) 2019-03-29 2025-11-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Antibodies against programmed cell death protein 1 (PD1) and uses thereof
CN113993887A (zh) 2019-06-19 2022-01-28 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生多价双特异性抗体表达细胞的方法
BR112021025462A2 (pt) 2019-06-19 2022-02-01 Hoffmann La Roche Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição
WO2020254352A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR20220010024A (ko) 2019-06-19 2022-01-25 에프. 호프만-라 로슈 아게 Cre mrna를 이용한 표적화된 통합에 의한 단백질 발현 세포의 산출을 위한 방법
JP7572977B2 (ja) 2019-06-19 2024-10-24 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
RU2770654C1 (ru) * 2021-06-17 2022-04-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе
WO2025039046A1 (en) * 2023-08-23 2025-02-27 The Walter And Eliza Hall Institute Of Medical Research Anti-rhesus d human monoclonal antibodies
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站（陕西省血液中心） 一种中和抗d抗体的抗独特型抗体及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002413A1 (en) 1983-11-28 1985-06-06 The Board Of Trustees Of The Leland Stanford Jr. U HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
GB8722019D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722018D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722020D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
GB8906129D0 (en) 1989-03-17 1989-05-04 Central Blood Lab Authority Pharmaceutical preparations
GB8919761D0 (en) 1989-09-01 1989-10-18 Central Blood Lab Authority Chemical compounds
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
CA2116246A1 (en) 1992-06-26 1994-01-06 Roland Beliard Human monoclonal anti-rhesus (d) antibodies and cell lines producing same
KR100306635B1 (ko) 1992-10-21 2001-11-30 스테판밀테니 분비생성물에의한직접적인세포선별
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
PT1231268E (pt) * 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
AU722127B2 (en) * 1996-06-24 2000-07-20 Zlb Behring Ag Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens, the DNA encoding them and the process for their preparation and use
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US5876925A (en) * 1996-10-11 1999-03-02 The Trustees Of The University Of Pennsylvania Magnetically activated cell sorting for production of proteins
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6187994B1 (en) 1997-11-18 2001-02-13 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
CN100365127C (zh) 1998-07-21 2008-01-30 密理博公司 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP4808880B2 (ja) 1999-07-23 2011-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア バクテリオファージｐｈｉｃ３１組み換え系による真核細胞におけるｄｎａ組み換え
EP1106625A1 (en) 1999-11-17 2001-06-13 ZLB Bioplasma AG Rhesus D specific peptide sequences
EP1358202A2 (en) 2000-02-08 2003-11-05 The Regents Of The University Of Michigan Protein separation and display
WO2001059460A2 (en) 2000-02-08 2001-08-16 The Regents Of The University Of Michigan Mapping of differential display of proteins
WO2001058926A2 (en) 2000-02-08 2001-08-16 The Regents Of The University Of Michigan Protein mapping
JP2003534290A (ja) 2000-05-26 2003-11-18 シムフォゲン アクティーゼルスカブ アレルギー治療用の組換えまたは精製ポリクロナール抗体
CA2416701A1 (en) 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agricul Ture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2002044361A2 (en) 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
WO2002052259A1 (en) 2000-12-26 2002-07-04 The Institute For Systems Biology Rapid and quantitative proteome analysis and related methods
WO2003102539A2 (en) 2002-05-31 2003-12-11 The Regents Of The University Of Michigan Automated protein analysis system comprising capillary electrophoresis-tandem mass spectrometry
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
WO2004035169A2 (en) 2002-10-15 2004-04-29 The Regents Of The University Of Michigan Multidimensional protein separation system
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
ES2273202T3 (es) * 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.

Also Published As

Publication number Publication date
EA014182B1 (ru) 2010-10-29
EP1967529A1 (en) 2008-09-10
US20120322690A1 (en) 2012-12-20
IL179658A0 (en) 2007-05-15
KR20070038556A (ko) 2007-04-10
US20090017017A1 (en) 2009-01-15
NO20070927L (no) 2007-04-19
AU2005263331A1 (en) 2006-01-26
EP1771483A1 (en) 2007-04-11
AU2005263331B8 (en) 2011-06-16
JP4926054B2 (ja) 2012-05-09
CA2574062A1 (en) 2006-01-26
EA200700249A1 (ru) 2007-06-29
JP2008509658A (ja) 2008-04-03
NZ552265A (en) 2009-04-30
US8198415B2 (en) 2012-06-12
AU2005263331A8 (en) 2011-06-16
MX2007000644A (es) 2007-03-28
AU2005263331B2 (en) 2011-05-26
WO2006007850A1 (en) 2006-01-26
IL179658A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
BRPI0513706A (pt) anticorpo policlonal recombinante anti-rhesus d e métodos de produção
Wu et al. Membrane engineering-a novel strategy to enhance the production and accumulation of β-carotene in Escherichia coli
BRPI0812091A2 (pt) Método para fabricar uma proteína policlonal recombinante
Jung et al. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing
BRPI0412138A (pt) anticorpo, hibridoma, método de produzir um anticorpo, composição farmacêutica, métodos de potencializar a atividade de célula, de detectar a presença de células nk e de purificar de uma amostra células nk, e, composição
Lin et al. Molecular basis for sculpting the endoplasmic reticulum membrane
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
UA116614C2 (uk) Антитіло до фактора d і його застосування
MX2010002044A (es) Metodos para produccion recombinante de anticuerpos anti-virus sincitial respiratorio (anti-rsv).
BRPI0924899B8 (pt) Síntese hmo
BR112012007854A2 (pt) metodos de produção de glicoproteínas em culturas de células de mamíferos usando glicocorticoides
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
BR112016025352A2 (pt) métodos de produção de uma biblioteca de clones de células eucarióticas, método de produção de um repertório diverso de ligantes, método de triagem para uma célula de um fenótipo desejado, método de triagem para um ligante que reconhece um alvo, biblioteca, biblioteca in vitro de clones de células eucarióticas, recipiente contendo células eucarióticas, uso de uma nuclease específica de sítio, usos da biblioteca, método para converter as populações de anticorpo de cadeia simples (scfv) em imunoglobulina (ig) ou fragmento, e método que permite a reformatação de quaisquer dois elementos de dna unidos a um vetor
BRPI0815370B8 (pt) anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
BR112022000394A2 (pt) Produção de fucosilactose em células hospedeiras
BR112012027430A2 (pt) processo de cultivo de células aprimorado
BR112019003622A2 (pt) método para produção de uma proteína de fusão.
Biarnes-Carrera et al. Orthogonal regulatory circuits for Escherichia coli based on the γ-butyrolactone system of Streptomyces coelicolor
BR112023008361A2 (pt) Variantes de glucoamilase e polinucleotídeos codificando as mesmas
WO2012092376A3 (en) Comprehensive monoclonal antibody generation
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
CN109072236A (zh) 用于生产分泌蛋白质的哺乳动物细胞

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2264 DE 27/05/2014.